BMPR2-IN-1 TFA

• CAT Number: I040042
• Molecular Formula: C18H16F3N7O3
• Molecular Weight: 435.36
• Purity: ≥95%
• Synonyms: 2,4,8,10,11,14,23-heptazatetracyclo[15.2.2.13,7.19,12]tricosa-1(19),3,5,7(23),9,12(22),17,20-octaen-13-one;2,2,2-trifluoroacetic acid
• InChI: InChI=1S/C16H15N7O.C2HF3O2/c24-15-12-9-14(23-22-12)20-13-6-8-18-16(21-13)19-11-3-1-10(2-4-11)5-7-17-15;3-2(4,5)1(6)7/h1-4,6,8-9H,5,7H2,(H,17,24)(H3,18,19,20,21,22,23);(H,6,7)
• InChIKey: OAWNZCPTZLYEGP-UHFFFAOYSA-N
• SMILES: C1CNC(=O)C2=CC(=NN2)NC3=NC(=NC=C3)NC4=CC=C1C=C4.C(=O)(C(F)(F)F)O

BMPR2-IN-1 TFA (Cat No.: I040042) is a selective inhibitor of bone morphogenetic protein receptor type 2 (BMPR2), a key regulator in pulmonary arterial hypertension (PAH), bone development, and cancer progression. By targeting BMPR2 signaling, it is used to study fibrosis, cardiovascular diseases, and tumorigenesis. The trifluoroacetate (TFA) salt enhances its solubility and stability for in vitro and in vivo applications. BMPR2-IN-1 TFA is a valuable tool in drug discovery, aiding in the development of novel therapeutic strategies for BMPR2-related diseases.

Reference

[1]. Amrhein JA, et al. Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2. ACS Med Chem Lett. 2023 May 30;14(6):833-840.
[Content Brief]